البلد: أيرلندا
اللغة: الإنجليزية
المصدر: HPRA (Health Products Regulatory Authority)
NIFEDIPINE
McDowell Pharmaceuticals
60 Milligram
Tablet Prolonged Release
2009-01-09
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PPA1473/005/002 Case No: 2050891 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to MCDOWELL PHARMACEUTICALS 4 ALTONA ROAD, LISBURN, N. IRELAND, BT27 5QB an authorisation, subject to the provisions of the said Regulations, in respect of the product ADALAT LA 60 MG PROLONGED-RELEASE TABLET The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 09/01/2009. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 13/01/2009_ _CRN 2050891_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Adalat LA 60mg Prolonged Release Tablet. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains 60 mg nifedipine. Excipients: Sodium For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM _Product imported from the UK_ Prolonged release film-coated tablet. Pink, circular convex tablets with ‘Adalat 60’ marked on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of all grades of hypertension. For the management of chronic stable angina pectoris either as monotherapy or in combination with a beta-blocker. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology For oral اقرأ الوثيقة كاملة